Articles related to ANTIMICROBIAL RESISTANCE

The FDA approved cefepime-zidebactam (Zaynich) for complicated UTI and pyelonephritis caused by susceptible gram-negative organisms. Approval followed phase 3 trial data showing higher rates of symptom and microbiologic resolution compared with meropenem in hospitalized adults.

Neonatal sepsis affects an estimated 22 per 1,000 live births globally and carries significant morbidity risk, with PA-authored CME examining risk stratification, diagnostic sequencing, and antimicrobial stewardship for the practicing provider.

A retrospective quasi-experimental study at St. Jude Children’s Research Hospital found that discontinuing empiric antibiotics within 72 hours of febrile neutropenia onset in clinically stable pediatric haploidentical HCT recipients reduced antibiotic exposure by a median of 8 days without significant differences in bloodstream infection, ICU admission, or mortality.

In a German prospective cohort of 1,017 MSM, PrEP use remained an independent risk factor for STI acquisition after adjustment for sexual behavior, with 71.8% diagnosed with at least one STI during follow-up.

Between 2019 and 2023, NDM-CRE infections, including pneumonia, bloodstream infections, urinary tract infections, and wound infections, surged by more than 460 percent in the United States.

Gepotidacin demonstrated superiority to nitrofurantoin in the EAGLE-3 trial with a therapeutic success rate of 58.9% versus 44%, while maintaining a manageable side effect profile primarily consisting of gastrointestinal disturbances.